Top-Rated Stocks NASDAQ:EXEL Exelixis - EXEL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.48 +0.15 (+0.82%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$17.90▼$18.5250-Day Range$16.30▼$18.5752-Week Range$14.87▼$23.40Volume8.62 million shsAverage Volume3.69 million shsMarket Capitalization$5.99 billionP/E Ratio32.42Dividend YieldN/APrice Target$26.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exelixis MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside40.7% Upside$26.00 Price TargetShort InterestHealthy2.80% of Shares Sold ShortDividend StrengthN/ASustainability-1.63Upright™ Environmental ScoreNews Sentiment0.36Based on 6 Articles This WeekInsider TradingSelling Shares$3.43 M Sold Last QuarterProj. Earnings Growth52.24%From $0.67 to $1.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.58 out of 5 starsMedical Sector3rd out of 989 stocksBiological Products, Except Diagnostic Industry1st out of 166 stocks 4.4 Analyst's Opinion Consensus RatingExelixis has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Exelixis has a forecasted upside of 40.7% from its current price of $18.48.Amount of Analyst CoverageExelixis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.80% of the outstanding shares of Exelixis have been sold short.Short Interest Ratio / Days to CoverExelixis has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exelixis has recently decreased by 14.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExelixis does not currently pay a dividend.Dividend GrowthExelixis does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExelixis has received a 64.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "VEGFR tyrosine kinase inhibitors", "Mitogen-activated protein kinase (MEK) inhibitors", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Exelixis is -1.63. Previous Next 1.9 News and Social Media Coverage News SentimentExelixis has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exelixis this week, compared to 6 articles on an average week.Social Mentions This WeekMarketBeat has tracked 4 reddit mentions for Exelixis this week, compared to 0 mentions on an average week.Search InterestOnly 30 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows9 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,433,100.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Exelixis is held by insiders.Percentage Held by Institutions84.74% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Exelixis are expected to grow by 52.24% in the coming year, from $0.67 to $1.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exelixis is 32.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Exelixis is 32.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.69.Price to Earnings Growth RatioExelixis has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioExelixis has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exelixis (NASDAQ:EXEL) StockExelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.Read More Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comExelixis Stock Shows Market Leadership, Earns 81 RS RatingMarch 20, 2023 | fool.comWhy Exelixis Stock Leaped More Than 4% Higher TodayMarch 25, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 20, 2023 | finance.yahoo.comExelixis Announces $550 Million Share Repurchase ProgramMarch 18, 2023 | finance.yahoo.com3 Beaten-Down Stocks That Could Soar This YearMarch 16, 2023 | finance.yahoo.comExelixis Stock Generating Improved Relative Strength RatingMarch 16, 2023 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Director Sells $254,133.00 in StockMarch 13, 2023 | finance.yahoo.comExelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes SummitMarch 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 10, 2023 | finance.yahoo.com2 Stocks to Buy With Less Than $20March 9, 2023 | finance.yahoo.comExelixis (EXEL) Down 7.9% Since Last Earnings Report: Can It Rebound?March 6, 2023 | finance.yahoo.comExelixis' (EXEL) Cabozantinib Combo Study Fails to Meet GoalMarch 3, 2023 | finance.yahoo.comExelixis stock falls as drug combo doesn’t improve kidney cancer survivalMarch 2, 2023 | finance.yahoo.comExelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney CancerMarch 2, 2023 | finance.yahoo.comExelixis stock falls as kidney cancer drug trial failsMarch 1, 2023 | finance.yahoo.comExelixis (NASDAQ:EXEL) investors are sitting on a loss of 32% if they invested five years agoFebruary 14, 2023 | finance.yahoo.comExelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805February 13, 2023 | finance.yahoo.comOpdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaFebruary 13, 2023 | finance.yahoo.comExelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid TumorsFebruary 9, 2023 | washingtonpost.comExelixis: Q4 Earnings SnapshotFebruary 9, 2023 | msn.comLooking Into Exelixis's Return On Capital EmployedFebruary 9, 2023 | finance.yahoo.comExelixis Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 8, 2023 | finance.yahoo.comExelixis (EXEL) Q4 Earnings Top, Revenues Beat on CabometyxFebruary 8, 2023 | finance.yahoo.comCompared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key MetricsFebruary 8, 2023 | fool.comExelixis (EXEL) Q4 2022 Earnings Call TranscriptFebruary 8, 2023 | finance.yahoo.comExelixis (EXEL) Reports Q4 Loss, Tops Revenue EstimatesFebruary 2, 2023 | finance.yahoo.comExelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruarySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Company Calendar Last Earnings2/07/2023Today3/25/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXEL CUSIP30161Q10 CIK939767 Webwww.exelixis.com Phone(650) 837-7000Fax650-837-8300Employees1,223Year Founded1994Price Target and Rating Average Stock Price Forecast$26.00 High Stock Price Forecast$32.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+40.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio32.42 Forward P/E Ratio27.58 P/E Growth0.76Net Income$182.28 million Net Margins11.31% Pretax Margin14.55% Return on Equity7.54% Return on Assets6.30% Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.89 Sales & Book Value Annual Sales$1.61 billion Price / Sales3.72 Cash Flow$0.62 per share Price / Cash Flow29.62 Book Value$7.68 per share Price / Book2.41Miscellaneous Outstanding Shares324,087,000Free Float314,688,000Market Cap$5.99 billion OptionableOptionable Beta0.69 Social Links Key ExecutivesMichael M. MorrisseyPresident, Chief Executive Officer & DirectorChristopher J. SennerChief Financial Officer & Executive Vice PresidentDana T. AftabChief Scientific Officer & Executive VP-DiscoveryVicki L. GoodmanChief Medical Officer & Executive Vice PresidentJeffrey J. HessekielSecretary, Executive VP & General CounselKey CompetitorsHalozyme TherapeuticsNASDAQ:HALONeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENBioCryst PharmaceuticalsNASDAQ:BCRXCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 4,074 shares on 3/23/2023Ownership: 0.066%Jack L WyszomierskiSold 15,300 sharesTotal: $254,133.00 ($16.61/share)Jeffrey HessekielSold 77,860 sharesTotal: $1.33 M ($17.13/share)Voya Investment Management LLCSold 38,455 shares on 2/28/2023Ownership: 0.097%Dana AftabSold 10 sharesTotal: $175.00 ($17.50/share)View All Insider TransactionsView All Institutional Transactions EXEL Stock - Frequently Asked Questions Should I buy or sell Exelixis stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares. View EXEL analyst ratings or view top-rated stocks. What is Exelixis' stock price forecast for 2023? 9 brokerages have issued 1-year price objectives for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they expect the company's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts. How have EXEL shares performed in 2023? Exelixis' stock was trading at $16.04 at the start of the year. Since then, EXEL stock has increased by 15.2% and is now trading at $18.48. View the best growth stocks for 2023 here. When is Exelixis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our EXEL earnings forecast. How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.04. The biotechnology company had revenue of $423.92 million for the quarter, compared to analyst estimates of $418.71 million. Exelixis had a net margin of 11.31% and a trailing twelve-month return on equity of 7.54%. The company's quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.29 earnings per share. What ETFs hold Exelixis' stock? ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), First Trust Health Care AlphaDEX Fund (FXH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Invesco S&P MidCap Quality ETF (XMHQ). What guidance has Exelixis issued on next quarter's earnings? Exelixis issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $415.00 million-$415.00 million, compared to the consensus revenue estimate of $414.83 million. What is Michael M. Morrissey's approval rating as Exelixis' CEO? 75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend. What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV). What is Exelixis' stock symbol? Exelixis trades on the NASDAQ under the ticker symbol "EXEL." Who are Exelixis' major shareholders? Exelixis' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.62%), Price T Rowe Associates Inc. MD (2.05%), Meditor Group Ltd (2.05%), Point72 Asset Management L.P. (1.98%), Geode Capital Management LLC (1.41%) and Dimensional Fund Advisors LP (1.36%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends. How do I buy shares of Exelixis? Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exelixis' stock price today? One share of EXEL stock can currently be purchased for approximately $18.48. How much money does Exelixis make? Exelixis (NASDAQ:EXEL) has a market capitalization of $5.99 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.57 on an earnings per share basis. How many employees does Exelixis have? The company employs 1,223 workers across the globe. How can I contact Exelixis? Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300. This page (NASDAQ:EXEL) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.